Skip to main content
Shanghai Junshi Biosciences Co.,Ltd. logo

Shanghai Junshi Biosciences Co.,Ltd. — Investor Relations & Filings

Ticker · 688180 ISIN · CNE1000041Z1 LEI · 300300L36FLCKN0WXW06 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,065 across all filing types
Latest filing 2026-06-05 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688180

About Shanghai Junshi Biosciences Co.,Ltd.

https://www.junshipharma.com/

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies. The company maintains a diverse pipeline targeting oncology, immunology, metabolic disorders, neurological diseases, and infectious diseases. A pioneer in its field, it developed Toripalimab, the first domestically produced anti-PD-1 monoclonal antibody to receive marketing approval in its home market. Its integrated R&D platform encompasses the entire drug development lifecycle, from initial discovery and clinical evaluation to large-scale manufacturing and global commercialization. The company collaborates with international partners to expand the reach of its innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, aiming to provide effective and affordable treatment options for patients globally.

Recent filings

Filing Released Lang Actions
科创板上市公司独立董事提名人声明与承诺（陈良）
Board/Management Information Classification · 87% confidence The document is a formal nomination statement and commitment by the board to propose an independent director candidate, detailing qualifications and compliance. This pertains to board composition and management changes rather than financial reporting, investor presentation, or regulatory filing, fitting the Board/Management Information category.
2026-06-05 Chinese
君实生物关于对外投资暨关联交易的公告
Capital/Financing Update Classification · 78% confidence The document is a formal exchange announcement by Shanghai Junshi Biosciences regarding its external investment and related-party transaction—injecting intellectual property and assets into a joint venture by subscribing to new capital. It is not a full financial report (10-K, IR), nor a simple publication notice or certification. It details a corporate financing activity (capital contribution) rather than a share buyback or executive change. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-06-05 Chinese
君实生物关于高级管理人员、核心技术人员变动，独立非执行董事任期届满离任暨补选独立非执行董事并调整董事会专门委员会的公告
Board/Management Information Classification · 96% confidence The document is an official announcement by Shanghai Junshi Biosciences regarding the resignation, term expiration and re-election of senior management and independent non-executive directors, and the adjustment of board committees. It details changes in board and management positions, in line with category definitions for board/management announcements. Therefore, it is classified as a Board/Management Information filing.
2026-06-05 Chinese
科创板上市公司独立董事候选人声明与承诺（陈良）
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a statement and undertaking by a nominee for independent director candidacy, detailing qualifications, independence criteria, and commitments. This type of material is typically part of proxy solicitation information sent to shareholders in advance of a vote at a general meeting (e.g., AGM/EGM) to elect board members. It is not the full proxy statement itself but is candidate-specific proxy information. Therefore the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2026-06-05 Chinese
国泰海通证券股份有限公司关于上海君实生物医药科技股份有限公司部分募投项目子项目实施主体股权结构变更的核查意见
Regulatory Filings Classification · 92% confidence The document is a sponsor’s verification opinion (“核查意见”) issued by Guotai Haitong Securities regarding an equity structure change of a project implementation subsidiary under the issuer’s fund-raising projects. It does not contain actual financial statements or initial earnings/annual reports, nor is it a shareholder meeting material, dividend notice, or proxy. It is primarily a regulatory compliance certification letter required by stock exchange rules, fitting the officer attestation/certification category. Under the certification rule and fallback guidelines, this is classified as a Regulatory Filing (RNS).
2026-06-05 Chinese
君实生物2025年年度股东会会议资料
AGM Information Classification · 98% confidence The document is the complete set of materials for the 2025 Annual General Meeting of shareholders (AGM): meeting notice, agenda, detailed proposals to be tabled and voted on (e.g., board work report, annual report approval, profit distribution, financing authorizations, director remuneration, auditor appointment, governance matters, etc.). It is not the report itself but the presentation materials for the AGM. This matches the definition of AGM Information (AGM-R).
2026-06-05 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.